Navigation Links
BioDelivery Sciences Provides Update on Ongoing Phase 3 Pivotal Trial for Clonidine Topical Gel for Painful Diabetic Neuropathy
Date:8/6/2014

tain the probability of a successful outcome," said Dr. Mark A. Sirgo, President and Chief Executive Officer. "Based on this information we will continue to progress other aspects of the clinical development program necessary for the NDA."

About BioDelivery Sciences International

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine.  BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

BDSI's development strategy focuses on utilization of the FDA's 505(b)(2) approval process. This regulatory pathway creates the potential for more timely and efficient approval of new formulations of previously approved therapeutics.

BDSI's particular area of focus is the development and commercialization of products in the areas of pain management and addiction. These are areas where BDSI believes its drug delivery technologies and products can best be applied to address critical unmet medical needs.  BDSI's marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, painful diabetic neuropathy and opioid dependence.

BDSI's headquarters is located in Raleigh, North Carolina. 

For more information visit www.bdsi.com.

BDSI can now be followed on Facebook (Facebook.com/BioDeliverySI) and Twitter (Twitter.com/BioDeliverySI)


'/>"/>
SOURCE BioDelivery Sciences International, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
2. BioDelivery Sciences and Endo Health Solutions Announce Initiation of Enrollment in the Phase 3 Program for BEMA Buprenorphine for Chronic Pain
3. BioDelivery Sciences to Present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference
4. BioDelivery Sciences Announces Completion of Enrollment in Pivotal Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
5. BioDelivery Sciences to Present at the Stifel Nicolaus 2012 Healthcare Conference
6. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
7. BioDelivery Sciences Provides Business Update and Summary of Third Quarter Results of Operations
8. BioDelivery Sciences to Present at the 24th Annual Piper Jaffray Healthcare Conference
9. BioDelivery Sciences Announces $40 Million Registered Financing
10. BioDelivery Sciences Announces Completion of BNX Safety Study
11. BioDelivery Sciences to Present at the 15th Annual BIO CEO and Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... -- Report Details   Translational ... progress, and predicted revenues ,Where is the market for ... prospects for this market and related technologies? Visiongain,s brand ... to 2025, discussing data, opportunities and prospects. ... medicine : cell-based therapies that aim to restore function ...
(Date:2/27/2015)... OF PRUSSIA, Pa. , Feb. 27, 2015 /PRNewswire/ ... of its ongoing commitment to the global bleeding disorders ... is donating 2 million international units (IUs) of protein ... is an international not-for- profit organization which has worked ... other inherited bleeding disorders. The donation supports the WFH,s ...
(Date:2/27/2015)...  PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... for the fourth quarter and full year ended December ... year for PTC. We are now a growing commercial-stage ... in the rare disease space," stated Stuart W. Peltz, ... proud to bring the first treatment for Duchenne muscular ...
Breaking Medicine Technology:Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11
(Date:3/1/2015)... March 01, 2015 The number of ... over the past few weeks in two New Jersey ... filing claims, the Firm announces. , A Case ... in the Bergen County proceeding established for products manufactured ... a few weeks earlier, when 90 fewer cases had ...
(Date:3/1/2015)... Aliso Viejo, California (PRWEB) March 01, 2015 ... have announced a new transition pack for ... users to add accordion style transitions to any FCPX ... Studios. “We’ve given our users the tools needed to ... FCPX media.” , The user gets many different controls ...
(Date:2/28/2015)... 01, 2015 Heart diseases are on ... percent of urban adult population and 5 percent of ... diseases and 20-30 percent of them require specialized investigation ... and coronary vascular diseases (CVD). , A division of ... market research report titled “Indian Coronary Stent Market Forecast ...
(Date:2/28/2015)... The Heart Fit Clinic started doing ... the machine. The Heart Fit Clinic is also selling ... franchise model. The goal is to scale the business ... To buy External Counterpulsation machines can be ... through this process and achieve the desired results. ...
(Date:2/28/2015)... 2015 Vancouver personal injury lawyers at Jiwa ... affected by time limits. They stated that in many cases, ... or even nullify it. Many a time, delays in making ... rights under BC law. As a result, experts at Jiwa ... should consult a personal injury lawyer in order to know ...
Breaking Medicine News(10 mins):Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2
... Steven Reinberg HealthDay Reporter , TUESDAY, Jan. 10 (HealthDay ... -- defined as men who down five or more drinks at ... one time, federal researchers reported Tuesday. Of the 17 percent ... 24 years old. But those 65 and older engage in the ...
... , INDIANAPOLIS -- The School of Science at Indiana ... Modeling and Computational Science, an interdisciplinary endeavor dedicated to ... the environment, and computer science. iM2CS,s parallel mission is ... the scientific issues with which they will be faced. ...
... , TUESDAY, Jan. 10 (HealthDay News) -- Dutch researchers ... the drug Nexavar (sorafenib) in fighting a tough-to-treat form ... experimental drug known as ganetespib showed promise in laboratory ... studies were to be presented Tuesday at an American ...
... Island Hospital has found that collaborative ,behavioral management may ... users who are paroled. The findings have important implications ... U.S. community correctional population. The study is published in ... of print. In the U.S., over 700,000 inmates ...
... January issue of Health Affairs assesses real-world ... chronic disease that affects nearly 26 million Americans. ... systematically reviewed the published literature and analyzed 28 studies ... trial in real-world settings. Published in 2002, this major ...
... HealthDay Reporter , MONDAY, Jan. 9 (HealthDay News) -- The ... the risk of heart attack, a new review finds. ... trials involving Pradaxa that included more than 30,000 patients. This ... to tease out a pattern that might not show up ...
Cached Medicine News:Health News:One in Six Americans Binge Drink: CDC 2Health News:One in Six Americans Binge Drink: CDC 3Health News:Revealing causality 2Health News:Mixed News on Tough-to-Treat Lung Cancer 2Health News:Mixed News on Tough-to-Treat Lung Cancer 3Health News:Behavioral management to reduce substance abuse, crime and re-arrest for drug-involved parolees 2Health News:Behavioral management to reduce substance abuse, crime and re-arrest for drug-involved parolees 3Health News:Diabetes study shines spotlight on lifestyle interventions 2Health News:Diabetes study shines spotlight on lifestyle interventions 3Health News:New Blood Thinner Linked to Higher Heart Attack Risk 2Health News:New Blood Thinner Linked to Higher Heart Attack Risk 3
Test for prostatic acid phosphatase...
For the quantitative measurement of human prostatic acid phosphatase (PAP) in human serum....
... a Windows 2000 PC based EEG with ... and software. EEG-9200 provides high quality performance ... in the sleep lab or EEG lab. ... the electrically noisy OR or ICU. Neurofax ...
... the first magnetic stimulator to offer the ... It is designed to provide the simplest ... routine (at the same time, it may ... can control operations without moving away from ...
Medicine Products: